We are developing pre-clinical screening tools to bring down the costs of drug discovery. About 90% of in-vitro drug screening is currently performed in 2D cell cultures which poorly represent 3D biology. Additionally, animal models compare poorly to human physiology due to species differences. As a result, many drugs with limited potential reach the clinical stages, leading to over 90% fail rate at the clinic alone.
In effect, we are developing a tool to enable non-promising drug candidates to fail before they reach the clinic, improving patient lives and saving substantial amounts of money in the process.